Clinical Trials
158 trialsSTELLAR-002
Exelixis
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Icahn School of Medicine at Mount Sinai
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
IMFINZI-subQ
AstraZeneca
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
Wondercel-UWD3
Wondercel Biotech (ShenZhen)
A Study of ZW251 in Participants With Advanced Solid Tumors
Zymeworks BC Inc.
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
PSI-Immune
University of Pittsburgh
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
PRESERVE-009
OncoC4, Inc.
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
ETCABIO
University Hospital, Angers
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Aptamer Sciences, Inc.
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
PNeoVCA
Mayo Clinic
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
SELECT-CAR-NK
Essen Biotech
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
TGI5
Hefei TG ImmunoPharma Co., Ltd.
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
EMITT-1
Grey Wolf Therapeutics
SIM0610-101
Jiangsu Simcere Pharmaceutical Co., Ltd.
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Incyte Corporation
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Study of GV20-0251 in Participants With Solid Tumor Malignancies
GV20 Therapeutics
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
BioInvent International AB
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer